Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Telik Announces Presentation and Webcast at 5th Annual OneMedForum Conference

January 4, 2012


PALO ALTO, Calif., Jan. 4, 2012 /PRNewswire/ — Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate update at the 5th Annual OneMedForum Conference on Wednesday, January 11 at 12:00 p.m. Pacific time (3:00 p.m. Eastern time) in San Francisco. A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of the presentation can be accessed for 30 days following the presentation.

About Telik
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company’s most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

SOURCE Telik, Inc.


Source: PR Newswire